These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9523800)

  • 1. Bayesian modeling of muscle biopsy contracture testing for malignant hyperthermia susceptibility.
    Loke JC; MacLennan DH
    Anesthesiology; 1998 Mar; 88(3):589-600. PubMed ID: 9523800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS.
    Allen GC; Larach MG; Kunselman AR
    Anesthesiology; 1998 Mar; 88(3):579-88. PubMed ID: 9523799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands.
    Islander G; Bendixen D; Ranklev-Twetman E; Ording H
    Acta Anaesthesiol Scand; 1996 May; 40(5):579-84. PubMed ID: 8792888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mathematical model to improve on phenotyping for molecular genetic research in malignant hyperthermia.
    Ginz HF; Rüffert H; Levano S; Li Wan Po A; Benthien J; Urwyler A; Girard T
    Pharmacogenet Genomics; 2009 Dec; 19(12):972-8. PubMed ID: 19890226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Malignant Hyperthermia - Diagnosis in Practice].
    Girard T; Bandschapp O
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2019 Sep; 54(9):538-548. PubMed ID: 31525787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. King-Denborough syndrome: contracture testing and literature review.
    Heiman-Patterson TD; Rosenberg HR; Binning CP; Tahmoush AJ
    Pediatr Neurol; 1986; 2(3):175-7. PubMed ID: 2907859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
    Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
    Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia.
    Hopkins PM; Ellis FR; Halsall PJ
    Br J Anaesth; 1991 May; 66(5):611-3. PubMed ID: 2031823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
    Urwyler A; Censier K; Kaufmann MA; Drewe J
    Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
    Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
    Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halothane-caffeine contracture testing in neuromuscular diseases.
    Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
    Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
    Allen GC; Rosenberg H; Fletcher JE
    Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetic testing for malignant hyperthermia susceptibility.
    Girard T; Treves S; Voronkov E; Siegemund M; Urwyler A
    Anesthesiology; 2004 May; 100(5):1076-80. PubMed ID: 15114203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy.
    Payen JF; Bosson JL; Bourdon L; Jacquot C; Le Bas JF; Stieglitz P; Benabid AL
    Anesthesiology; 1993 May; 78(5):848-55. PubMed ID: 8489056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viability criterion of muscle bundles used in the in vitro contracture test in patients with neuromuscular diseases.
    Adnet PJ; Krivosic-Horber RM; Krivosic I; Haudecoeur G; Reyford HG; Adamantidis MM; Medahoui H
    Br J Anaesth; 1994 Jan; 72(1):93-7. PubMed ID: 8110560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
    Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U
    Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.